Novartis (NYSE: NVS) reported Q3 EPS of $2.25, $0.02 worse than the analyst estimate of $2.27. Revenue for the quarter came in at $13.91 billion versus the consensus estimate of $13.89 billion.

GUIDANCE

Sales expected to grow high single-digit. Core operating income expected to grow low-teens.

For earnings history and earnings-related data on Novartis (NVS) click here.